SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003; 2: 64653.
  • 2
    Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66: 144755.
  • 3
    Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 2006; 367: 126270.
  • 4
    Brooks LG, Loewenstein DA. Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther 2010; 2: 19.
  • 5
    De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 94956.
  • 6
    Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010; 9: 56074.
  • 7
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 2709.
  • 8
    Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009; 30: 68290.
  • 9
    Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 3439.
  • 10
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 22834.
  • 11
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 38593.
  • 12
    Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 61927.
  • 13
    Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, DiBernardo A, Narayan V; Alzheimer's Disease Neuroimaging Initiative. An improved model for disease progression in subjects from Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 2012; 52: 62944.
  • 14
    Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, DiBernardo A, Narayan V. An improved model for disease progression in subjects from Alzheimer's disease neuroimaging initiative [Internet]. In: American Conference on Pharmacometrics (ACoP). San Diego: 2011. Available at: http://www.go-acop.org/sites/default/files/webform/posters/ACOP-Poster.ppt (last accessed 8 June 2011).
  • 15
    Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6: 295303.
  • 16
    Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM, Alzheimer's Disease Neuroimaging Initiative. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011; 122: 40113.
  • 17
    Boeckman A, Sheiner A, Beal S. NONMEM VI. GloboMax, ICON Development Solutions: Ellicott City, MD, 2007.
  • 18
    Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 2000; 19: 160716.
  • 19
    Stern Y, Liu X, Albert M, Brandt J, Jacobs DM, Del Castillo-Castaneda C, Marder K, Bell K, Sano M, Bylsma F, Lafleche G, Tsai WY. Application of a growth curve approach to modeling the progression of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1996; 51: M17984.
  • 20
    Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep 2001; 3: 208.
  • 21
    van Belle G, Uhlmann RF, Hughes JP, Larson EB. Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. J Clin Epidemiol 1990; 43: 58995.
  • 22
    Liu X, Tsai WY, Stern Y. A functional decline model for prevalent cohort data. Stat Med 1996; 15: 102332.
  • 23
    Tsoularis A, Wallace J. Analysis of logistic growth models. Math Biosci 2002; 179: 2155.
  • 24
    Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 3906.
  • 25
    Carroll RJ, Ruppert D. Transformations and Weighting in Regression. New York: Chapman & Hall, 1988; 11560.
  • 26
    Bonate P. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer, 2006; 14144.
  • 27
    Kaila N, Straka RJ, Brundage RC. Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinet Pharmacodyn 2007; 34: 14156.
  • 28
    Beal SL, Boeckman AJ, Sheiner LB, eds. NONMEM Users Guide – Part VI. PREDPP Guide. San Francisco, CA: NONMEM Project Group, University of California, 1992; 356.
  • 29
    Ette EI, Williams PJ, eds. Pharmacometrics: The Science of Quantitative Pharmacology. New York: Wiley, John & Sons, Incorporated, 2007; 72357.
  • 30
    Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004; 31: 10934.
  • 31
    Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T, Alzheimer's Disease Neuroimaging Initiative. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement 2011; 7: 15160.
  • 32
    Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 2009; 68: 66981.
  • 33
    Wählby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4: E27.
  • 34
    Lindbom L, Philgren P, Jonsson N. PsN-Toolkit-a collection of computer intensive statistical methods for nonlinear mixed effect modelling using NONMEM. Comput Methods Programs Biomed 2005; 79: 24157.
  • 35
    Holford N. The visual predictive check – superiority to standard diagnostic (Rorschach) plots. PAGE 2005; 14: 738 (Abstr.).
  • 36
    Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 2019.
  • 37
    Schilling MF, Watkins AE, Watkins W. Is human height bimodal? Am Stat 2002; 56: 2239.
  • 38
    Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 11928.
  • 39
    Chauhan NB. Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. J Lipid Res 2003; 44: 201929.
  • 40
    Leduc V, Jasmin-Bélanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 2010; 16: 46977.
  • 41
    Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol 2005; 4: 84152.
  • 42
    van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, van der Flier WM. Hippocampal atrophy in Alzheimer disease: age matters. Neurology 2006; 66: 2368.
  • 43
    European Medicines Agency. Qualification Opinion of Alzheimer's Disease Novel Methodologies/Biomarkers for BMS-708163. London: EMA, 2011; Doc Reference number EMA/CHMP/SAWP/102001/2011.
  • 44
    ClinicalTrial.gov. A multicenter, double blind, placebo-controlled, safety and tolerability study of BMS-708163 in patients with prodromal Alzheimer's disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00890890 (last accessed 21 May 2012).
  • 45
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98106.
  • 46
    Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66: 63845.
  • 47
    Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, Weiner MW, Aisen P, Alzheimer's Disease Neuroimaging Initiative. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials 2011; 32: 68593.
  • 48
    Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 38695.
  • 49
    Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597609.
  • 50
    Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012; 8: 6573.